Search

Your search keyword '"Capolongo, Antonio"' showing total 26 results
Start Over Author "Capolongo, Antonio"
26 results on '"Capolongo, Antonio"'

1. ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor

Author

Benenati, Stefano, Gragnano, Felice, Scalamera, Riccardo, De Sio, Vincenzo, Capolongo, Antonio, Cesaro, Arturo, Annibali, Gianmarco, Campagnuolo, Salvatore, Silverio, Angelo, Bellino, Michele, Centore, Mario, Schettino, Matteo, Bertero, Edoardo, Caretta, Giorgio, Rezzaghi, Marco, Veneziano, Francesco, De Nardo, Davide, De Rosa, Gennaro, De Luca, Leonardo, Galasso, Gennaro, Menozzi, Alberto, Musumeci, Giuseppe, Cirillo, Plinio, Calabrò, Paolo, and Porto, Italo

Published
2024
Full Text
View/download PDF

3. Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Author

Gragnano, Felice, primary, Capolongo, Antonio, additional, Micari, Antonio, additional, Costa, Francesco, additional, Garcia-Ruiz, Victoria, additional, De Sio, Vincenzo, additional, Terracciano, Fabrizia, additional, Cesaro, Arturo, additional, Moscarella, Elisabetta, additional, Coletta, Silvio, additional, Raucci, Pasquale, additional, Fimiani, Fabio, additional, De Luca, Leonardo, additional, Gargiulo, Giuseppe, additional, Andò, Giuseppe, additional, and Calabrò, Paolo, additional

Published
2023
Full Text
View/download PDF

6. New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention

Author

Gragnano, Felice, Capolongo, Antonio, Terracciano, Fabrizia, Gargiulo, Giuseppe, Cesaro, Arturo, Moscarella, Elisabetta, De Sio, Vincenzo, Patti, Giuseppe, Porto, Italo, Esposito, Giovanni, Calabro', Paolo, Gragnano, Felice, Capolongo, Antonio, Terracciano, Fabrizia, Gargiulo, Giuseppe, Cesaro, Arturo, Moscarella, Elisabetta, De Sio, Vincenzo, Patti, Giuseppe, Porto, Italo, Esposito, Giovanni, and Calabro', Paolo

Abstract

Dual antiplatelet therapy (DAPT) is a cornerstone in the management of patients with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI). The use of intensified or prolonged antithrombotic regimens is invariably associated with a reduction in ischemic risk yet an increase in the risk of bleeding complications. The selection of the optimal antiplatelet therapy in each individual patient remains therefore crucial. In recent years, novel approaches alternative to the conventional DAPT and based on the escalation or de-escalation of P2Y12 antagonists have been proposed. These strategies, chosen according to clinical features, genetic factors, and platelet function, have been developed to optimize and individualize the treatment of patients with coronary artery disease and improve their prognosis. In this review, we summarize recent evidence about escalation and de-escalation strategies (guided and unguided), and discuss the utility of genetic and platelet function tests in patients with ACS and/or undergoing PCI.

Published
2023

7. Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

Author

Gragnano, Felice, Capolongo, Antonio, Micari, Antonio, Costa, Francesco, Garcia-Ruiz, Victoria, De Sio, Vincenzo, Terracciano, Fabrizia, Cesaro, Arturo, Moscarella, Elisabetta, Coletta, Silvio, Raucci, Pasquale, Fimiani, Fabio, De Luca, Leonardo, Gargiulo, Giuseppe, Andò, Giuseppe, and Calabrò, Paolo

Subjects
*MYOCARDIAL infarction, *FIBRINOLYTIC agents, *PERCUTANEOUS coronary intervention, *ATRIAL fibrillation, *PLATELET aggregation inhibitors, *OLDER patients
Abstract

The antithrombotic management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) poses numerous challenges. Triple antithrombotic therapy (TAT), which combines dual antiplatelet therapy (DAPT) with oral anticoagulation (OAC), provides anti-ischemic protection but increases the risk of bleeding. Therefore, TAT is generally limited to a short phase (1 week) after PCI, followed by aspirin withdrawal and continuation of 6–12 months of dual antithrombotic therapy (DAT), comprising OAC plus clopidogrel, followed by OAC alone. This pharmacological approach has been shown to mitigate bleeding risk while preserving adequate anti-ischemic efficacy. However, the decision-making process remains complex in elderly patients and those with co-morbidities, significantly influencing ischemic and bleeding risk. In this review, we discuss the available evidence in this area from randomized clinical trials and meta-analyses for post-procedural antithrombotic therapies in patients with non-valvular AF undergoing PCI. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. 349 INTRAVENOUS CANGRELOR INFUSION IN PATIENTS UNDERGOING COMPLEX VERSUS NON-COMPLEX PERCUTANEOUS CORONARY INTERVENTION: A SUBANALYSIS OF THE ICARUS REGISTRY

Author

Gragnano, Felice, primary, Benenati, Stefano, additional, Scalamera, Riccardo, additional, Bertero, Edoardo, additional, Capolongo, Antonio, additional, De Sio, Vincenzo, additional, Musumeci, Giuseppe, additional, Annibali, Gianmarco, additional, Campagnuolo, Salvatore, additional, Galasso, Gennaro, additional, Silverio, Angelo, additional, Bellino, Michele, additional, Centore, Mario, additional, Menozzi, Alberto, additional, Caretta, Giorgio, additional, Rezzaghi, Marco, additional, De Luca, Leonardo, additional, Veneziano, Francesco Antonio, additional, Cirillo, Plinio, additional, De Rosa, Gennaro, additional, Porto, Italo, additional, and Calabrò, Paolo, additional

Published
2022
Full Text
View/download PDF

10. 330 INTRAVENOUS CANGRELOR INFUSION IN HIGH BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: PRELIMINARY RESULTS OF THE ICARUS REGISTRY

Author

Benenati, Stefano, primary, Gragnano, Felice, additional, Scalamera, Riccardo, additional, Bertero, Edoardo, additional, Capolongo, Antonio, additional, Sio, Vincenzo De, additional, Musumeci, Giuseppe, additional, Annibali, Gianmarco, additional, Campagnuolo, Salvatore, additional, Galasso, Gennaro, additional, Silverio, Angelo, additional, Bellino, Michele, additional, Centore, Mario, additional, Menozzi, Alberto, additional, Caretta, Giorgio, additional, Rezzaghi, Marco, additional, Luca, Leonardo De, additional, Veneziano, Francesco Antonio, additional, Cirillo, Plinio, additional, Rosa, Gennaro De, additional, Calabrò, Paolo, additional, and Porto, Italo, additional

Published
2022
Full Text
View/download PDF

11. 910 PREVALENCE AND PROGNOSTIC IMPACT OF ANAEMIA IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION AND RECEIVING CANGRELOR: A SUBANALYSIS OF THE ICARUS REGISTRY

Author

Capolongo, Antonio, primary, Gragnano, Feliceg, additional, Benenati, Stefano, additional, De Sio, Vincenzo, additional, Scalamera, Riccardo, additional, Bertero, Edoardo, additional, Musumeci, Giuseppe, additional, Annibali, Gianmarco, additional, Campagnuolo, Salvatore, additional, Galasso, Gennaro, additional, Silverio, Angelo, additional, Belllino, Michele, additional, Centore, Mario, additional, Menozzi, Alberto, additional, Caretta, Giorgio, additional, Rezzaghi, Marco, additional, De Luca, Leonardo, additional, Antonio Veneziano, Francesco, additional, Cirillo, Plinio, additional, De Rosa, Gennaro, additional, Porto, Italo, additional, and Calabrò, Paolo, additional

Published
2022
Full Text
View/download PDF

12. 345 INTRAVENOUS CANGRELOR INFUSION IN ELDERLY PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A SUBANALYSIS OF THE ICARUS REGISTRY

Author

Benenati, Stefano, primary, Gragnano, Felice, additional, Capolongo, Antonio, additional, De Sio, Vincenzo, additional, Scalamera, Riccardo, additional, Bertero, Edoardo, additional, Musumeci, Giuseppe, additional, Annibali, Gianmarco, additional, Campagnuolo, Salvatore, additional, Galasso, Gennaro, additional, Silverio, Angelo, additional, Bellino, Michele, additional, Centore, Mario, additional, Menozzi, Alberto, additional, Caretta, Giorgio, additional, Rezzaghi, Marco, additional, De Luca, Leonardo, additional, Antonio Veneziano, Francesco, additional, Cirillo, Plinio, additional, De Rosa, Gennaro, additional, Calabrò, Paolo, additional, and Porto, Italo, additional

Published
2022
Full Text
View/download PDF

13. 902 INCIDENCE, CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS PRESENTING WITH VERSUS WITHOUT CARDIOGENIC SHOCK AND RECEIVING CANGRELOR: AN EXPLORATORY SUBANALYSIS OF THE ICARUS REGISTRY

Author

Scalamera, Riccardo, primary, Benenati, Stefano, additional, Gragnano, Felice, additional, Bertero, Edoardo, additional, Capolongo, Antonio, additional, De Sio, Vincenzo, additional, Musumeci, Giuseppe, additional, Annibali, Gianmarco, additional, Campagnuolo, Salvatore, additional, Galasso, Gennaro, additional, Silverio, Angelo, additional, Belllino, Michele, additional, Centore, Mario, additional, Menozzi, Alberto, additional, Caretta, Giorgio, additional, Rezzaghi, Marco, additional, De Luca, Leonardo, additional, Antonio Veneziano, Francesco, additional, Cirillo, Plinio, additional, De Rosa, Gennaro, additional, Calabrò, Paolo, additional, and Porto, Italo, additional

Published
2022
Full Text
View/download PDF

14. Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice

Author

Gragnano, Felice, primary, Capolongo, Antonio, additional, Terracciano, Fabrizia, additional, Gargiulo, Giuseppe, additional, De Sio, Vincenzo, additional, Cesaro, Arturo, additional, Moscarella, Elisabetta, additional, Patti, Giuseppe, additional, Porto, Italo, additional, Esposito, Giovanni, additional, Angiolillo, Dominick J., additional, and Calabrò, Paolo, additional

Published
2022
Full Text
View/download PDF

15. De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine.

Author

Gragnano, Felice, Capolongo, Antonio, Terracciano, Fabrizia, De Sio, Vincenzo, Maddaluna, Pasquale, Fimiani, Fabio, Moscarella, Elisabetta, Cesaro, Arturo, Montone, Rocco A., Bianco, Roberto, Lisi, Danilo, Mensorio, Mario Massimo, Annecchiarico, Angela, and Calabrò, Paolo

Subjects
ACUTE coronary syndrome, INDIVIDUALIZED medicine, PROGNOSIS, PLATELET aggregation inhibitors, PERCUTANEOUS coronary intervention, PLATELET function tests
Abstract

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is a cornerstone in the treatment of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Current international guidelines recommend the use of 12 months of DAPT with newer P2Y12 inhibitors (i.e. ticagrelor or prasugrel) as first-line therapy in this setting. However, intense and prolonged DAPT regimens are associated with an increased risk of bleeding, with relevant prognostic implications. Recently, a strategy of de-escalation of P2Y12 inhibitors has been proposed as an alternative to conventional DAPT to mitigate the risk of bleeding while preserving ischemic protection after ACS. In this review, we summarize the available evidence on guided and unguided strategies for P2Y12 inhibitor de-escalation in patients with ACS undergoing PCI. Among patients with ACS, guided and unguided de-escalation strategies are safe and effective for secondary cardiovascular prevention. Although the implementation of genetic and platelet function tests is of interest for treatment personalization, the routine use of guided de-escalation strategies seems impractical. In this context, unguided de-escalation approaches appear more attractive, convenient, and suitable for contemporary practice. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Effect of Temperature, pH,Ionic Strength, and Sodium Nitrate on Activity of LiPs: Implications for Bioremediation.

Author

Bosco, Francesca, Capolongo, Antonio, and Ruggeri, Bernardo

Subjects
*TEMPERATURE, *HYDROGEN-ion concentration, *BIOREMEDIATION, *ENZYMES
Abstract

The present work is aimed to show the effects of environmental parameters such as temperature, pH, ionic strength, and sodium nitrate on enzyme activity of a LiP Isoenzymes Mixture (LIM) obtained from an immobilized culture of Phanerochaete chrysosporium. LIM enzyme stability was also evaluated. The results are discussed in detail and a comparison with literature data is carried out. LIM showed high activity at pH 3.0 in the temperature range 30 to 40 °C, it is able to catalyze oxidation reactions at acid pH (2.5 < pH < 6) and over a wide range of temperatures (25 to 60°C). Ionic strength below 0.2 M had no effect on enzyme activity at pH 4.7 and 39 °C. An evaluation of the time decay constant of LIM activity under a specific combination of parameters was also conducted. Finally, an LIM activity and durability map shows the optimal working conditions that might be suitable for its practical application in waste bioremediation processes. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

26. [New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention].

Author

Gragnano F, Capolongo A, Terracciano F, Gargiulo G, Cesaro A, Moscarella E, De Sio V, Patti G, Porto I, Esposito G, and Calabrò P

Subjects
Humans, Platelet Aggregation Inhibitors, Hemorrhage chemically induced, Hemorrhage prevention & control, Dual Anti-Platelet Therapy, Treatment Outcome, Acute Coronary Syndrome drug therapy, Acute Coronary Syndrome etiology, Percutaneous Coronary Intervention adverse effects
Abstract

Dual antiplatelet therapy (DAPT) is a cornerstone in the management of patients with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI). The use of intensified or prolonged antithrombotic regimens is invariably associated with a reduction in ischemic risk yet an increase in the risk of bleeding complications. The selection of the optimal antiplatelet therapy in each individual patient remains therefore crucial. In recent years, novel approaches alternative to the conventional DAPT and based on the escalation or de-escalation of P2Y12 antagonists have been proposed. These strategies, chosen according to clinical features, genetic factors, and platelet function, have been developed to optimize and individualize the treatment of patients with coronary artery disease and improve their prognosis. In this review, we summarize recent evidence about escalation and de-escalation strategies (guided and unguided), and discuss the utility of genetic and platelet function tests in patients with ACS and/or undergoing PCI.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results